Geriflo-D Tablet SR is a combination medication containing Tamsulosin 0.4 mg and Dutasteride 0.5 mg, indicated for the management of benign prostatic hyperplasia (BPH). Tamsulosin, an alpha-1 adrenergic receptor antagonist, facilitates the relaxation of smooth muscle in the prostate and bladder neck, thereby improving urine flow and reducing BPH-related symptoms such as urinary frequency, urgency, and nocturia. Dutasteride, a 5-alpha-reductase inhibitor, decreases the conversion of testosterone to dihydrotestosterone (DHT), a hormone responsible for prostate enlargement, leading to a reduction in prostate volume over time. The sustained-release formulation ensures a steady plasma concentration, enhancing therapeutic efficacy and patient compliance. Geriflo-D is typically prescribed for men with moderate to severe BPH, especially those with an enlarged prostate, to alleviate lower urinary tract symptoms and reduce the risk of acute urinary retention or the need for surgical intervention. Patients should be monitored for potential side effects including dizziness, hypotension, sexual dysfunction, and possible allergic reactions. Caution is advised in patients with hepatic impairment or a history of hypersensitivity to either component. Regular follow-up is recommended to assess symptom improvement and adverse effects.